3.200NOK-3.03%Mkt Cap: 86.26M NOKP/E: —Last update: 2026-06-01
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europ…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap86.26M NOK
Enterprise Value149.99M NOK
Revenue (TTM)42.62M NOK
Gross Profit11.04M NOK
Net Income (TTM)-41.03M NOK
Revenue/Share1.579 NOK
Last Price3.200 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees19
CountryNO
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-16.50
PEG—
EV/EBITDA-4.90
EV/Revenue3.52
P/S2.09
P/B0.51
EPS (TTM)-1.52
EPS (Forward)-0.20
52W Range
2.82019% of range4.800
52W High4.800 NOK
52W Low2.820 NOK
Profitability
Gross Margin27.54%
Oper. Margin-72.20%
EBITDA Margin-71.79%
Profit Margin-102.32%
ROE-23.65%
ROA-14.41%
Growth
Revenue Growth-12.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.65M NOK
CapEx (TTM)22.75M NOK
FCF Margin-84.68%
FCF Yield-41.83%
Net Debt61.03M NOK
Net Debt/EBITDA-1.99
Balance Sheet
Debt/Equity0.37
Current Ratio0.59
Quick Ratio0.24
Book Value/Sh6.436 NOK
Cash/Share0.0480 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.26.96M
Float12.87M
Insiders52.25%
Institutions1.44%
Technical
SMA 503.301 (-3.1%)
SMA 2003.482 (-8.1%)
Beta1.09
S&P 52W Chg27.70%
Avg Vol (30d)23.70K
Avg Vol (10d)22.25K
Technical Indicators
RSI (14)51.0
MACD-0.0282
MACD Signal-0.0315
MACD Hist.+0.0033
BB Upper3.512 NOK
BB Middle3.252 NOK
BB Lower2.992 NOK
BB Width15.98%
ATR (14)0.2617 NOK
Vol Ratio (20d)0.10x